PPARA and metabolic dysfunction-associated steatotic liver disease: A recent small study of 10 biopsy-proven NASH patients showed improvements with permafibrate therapy by non-invasive assessments of fibrosis (fibrosis-4 index, aspartate aminotransferase-to-platelet ratio index), further supporting a potential role for PPARα in the treatment of NAFLD [117].